Clinical Trial: Transformative Study of Orelabrutinib Combined with Pola-R-CHP Regimen in the First-Line Treatment of Patients with Intermediate-High Risk Diffuse Large B-Cell Lymphoma (DLBCL) (China)

Posted On: 2026-10-12

China, Oct. 12 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Transformative Study of Orelabrutinib Combined with Pola-R-CHP Regimen in the First-Line Treatment of Patients with Intermediate-High Risk Diffuse Large B-Cell Lymphoma (DLBCL)'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600134152

Registration Time: 2026/10/11

Type: Interventional study

Primary Sponsor: The First Affiliated Hospital of Xiamen University

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=299023

Published by HT Digital Content Services with permission from Health Daily Digest....

Click here to read full article from source

इस लेख के रीप्रिंट को खरीदने या इस प्रकाशन का पूरा फ़ीड प्राप्त करने के लिए, कृपया हमे संपर्क करें.

विशेष

Category

Source

Publication

Location

Clinical Trial: Transformative Study of Orelabrutinib Combined with Pola-R-CHP Regimen in the First-Line Treatment of Patients with Intermediate-High Risk Diffuse Large B-Cell Lymphoma (DLBCL) (China)